Bestat USA Presented at Phoenix Biomedical Forum
On June 18, 2026, Dr. Gary Lin, CEO of Bestat USA Inc. ("BUS"), the U.S. subsidiary of Bestat Group, introduced BUS at a forum held as part of the "Phoenix Biomedical Business Delegation" led by the Biomedical Industry Promotion Office of the Ministry of Economic Affairs (BPIPO). During the session, Dr. Lin shared BUS's establishment background, service positioning, and future development plans with biotech and pharmaceutical industry leaders, receiving enthusiastic feedback from attendees.
BUS's operations office is located in Phoenix, Arizona, an emerging biotechnology hub in the United States. In recent years, Phoenix has developed a growing biomedical ecosystem, bringing together biomedical institutions, medical centers, and industry resources that provide a favorable environment for clinical research and biomedical innovation. Bestat's decision to establish Phoenix as a key base for its North American expansion reflects the city's strategic value in connecting with the U.S. market and international partners.
During the forum, Dr. Gary Lin explained that BUS has initially focused on clinical project management and site management services. By the end of 2026, BUS plans to further expand its service scope to include Investigational New Drug (IND) consulting, Institutional Review Board (IRB) submissions, and subject recruitment, gradually building more comprehensive clinical trial service capabilities in the United States.
As an important part of Bestat Group's international expansion strategy, the development of BUS not only represents Bestat's continued efforts to bring Taiwan's CRO expertise to overseas markets, but also reflects the Group's commitment to building a cross-border clinical research service platform. Through professional collaboration and resource integration between its Taiwan and U.S. teams, Bestat aims to provide biotech and pharmaceutical companies with more flexible clinical development support that is closely aligned with international market needs.
The exchange at the Phoenix biomedical forum also demonstrated Bestat Group's growing potential in the North American market. Through interaction with local biotech and pharmaceutical partners, medical institutions, and related organizations, Bestat will continue to expand its international collaboration network and create more opportunities for future cross-border clinical trials and biomedical R&D partnerships.
This engagement also aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 9: Industry, Innovation and Infrastructure and SDG 17: Partnerships for the Goals. By establishing an overseas presence and promoting cross-border collaboration, Bestat continues to strengthen the innovation foundation of biopharmaceutical R&D services while fostering international partnerships and industry resource integration. In addition, by supporting clinical trials and new drug development, Bestat also contributes to SDG 3: Good Health and Well-being, advancing medical progress and improving human health.
Looking to the future, Bestat Group will continue to deepen its presence in North America, integrate the professional strengths of its Taiwan and U.S. teams, and support more biotech and pharmaceutical companies in advancing clinical development. Through these efforts, Bestat aims to bring the professional value of Taiwan's CRO services to a broader international stage.
On June 18, 2026, Dr. Gary Lin, CEO of Bestat USA Inc. ("BUS"), the U.S. subsidiary of Bestat Group, introduced BUS at a forum held as part of the "Phoenix Biomedical Business Delegation" led by the Biomedical Industry Promotion Office of the Ministry of Economic Affairs (BPIPO). During the session, Dr. Lin shared BUS's establishment background, service positioning, and future development plans with biotech and pharmaceutical industry leaders, receiving enthusiastic feedback from attendees.
BUS's operations office is located in Phoenix, Arizona, an emerging biotechnology hub in the United States. In recent years, Phoenix has developed a growing biomedical ecosystem, bringing together biomedical institutions, medical centers, and industry resources that provide a favorable environment for clinical research and biomedical innovation. Bestat's decision to establish Phoenix as a key base for its North American expansion reflects the city's strategic value in connecting with the U.S. market and international partners.
During the forum, Dr. Gary Lin explained that BUS has initially focused on clinical project management and site management services. By the end of 2026, BUS plans to further expand its service scope to include Investigational New Drug (IND) consulting, Institutional Review Board (IRB) submissions, and subject recruitment, gradually building more comprehensive clinical trial service capabilities in the United States.
As an important part of Bestat Group's international expansion strategy, the development of BUS not only represents Bestat's continued efforts to bring Taiwan's CRO expertise to overseas markets, but also reflects the Group's commitment to building a cross-border clinical research service platform. Through professional collaboration and resource integration between its Taiwan and U.S. teams, Bestat aims to provide biotech and pharmaceutical companies with more flexible clinical development support that is closely aligned with international market needs.
The exchange at the Phoenix biomedical forum also demonstrated Bestat Group's growing potential in the North American market. Through interaction with local biotech and pharmaceutical partners, medical institutions, and related organizations, Bestat will continue to expand its international collaboration network and create more opportunities for future cross-border clinical trials and biomedical R&D partnerships.
This engagement also aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 9: Industry, Innovation and Infrastructure and SDG 17: Partnerships for the Goals. By establishing an overseas presence and promoting cross-border collaboration, Bestat continues to strengthen the innovation foundation of biopharmaceutical R&D services while fostering international partnerships and industry resource integration. In addition, by supporting clinical trials and new drug development, Bestat also contributes to SDG 3: Good Health and Well-being, advancing medical progress and improving human health.
Looking to the future, Bestat Group will continue to deepen its presence in North America, integrate the professional strengths of its Taiwan and U.S. teams, and support more biotech and pharmaceutical companies in advancing clinical development. Through these efforts, Bestat aims to bring the professional value of Taiwan's CRO services to a broader international stage.